摘要
目的:探讨辛伐他汀对急性冠脉综合征(ACS)患者血清白介素-6(IL-6)及一氧化氮(NO)含量变化的影响,上述因子变化与ACS发病的关系及辛伐他汀对ACS的疗效。方法:55例ACS患者随机被分为辛伐他汀组 (n=27例)和常规治疗组(n=28例),分别于治疗前及治疗后3周行血清IL-6及NO检测。另选本院同期健康体检的30例作为对照组,对照组采血前2周内未服任何药物。结果:①ACS患者血清IL-6水平明显高于正常组,NO 水平显著低于正常组(P均<0．01);②辛伐他汀治疗后,血清IL～6水平明显降低,NO水平显著升高(P均< 0．01),但两组的IL-6、NO水平仍与正常组的有明显差别(P<0．01);③常规治疗后,血清IL-6、NO均变化不明显(P>0．05)。结论:辛伐他汀可降低急性冠脉综合征患者血IL-6水平,升高NO水平,保护血管内皮的功能。
Objective： To study the effect of simvastatin on the level change of serum interleukin-6 （IL-6） and nitric oxide （NO） in the patients with acute coronary syndromes （ACS） ; to find the correlation between the change of two factors levels and ACS and the role of simvastatin on ACS. Methods ： A total of 55 ACS patients were randomly divid- ed into simvastatin group （27 cases） and routine therapy （28cases） group. Serum IL-6 and NO levels were measured before treatment and after three weeks respectively. In addition, 30 healthy check-up people, who didn＇t take any medicine in two weeks before blood sampling, were selected as a control group. Results： ①The level of IL-6 was higher and NO content was lower in ACS patients companied with those of the normal group, （P〈0.01 all）;②In simvastatin group the level of IL-6 decreased significantly and NO content increased markedly after therapy （P〈 0.01, all）, but them still differed from those of normal group （P〈0.01） ; ③The values of IL-6 and NO changed slightly after routine therapy （P〈0.05）. Conclusion： Simvastatin can reduce the levels of IL-6, increase NO content and improve the endothelial function in ACS patients.
出处
《心血管康复医学杂志》
CAS
2006年第1期57-59,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
